Message	
From:	Sunny Balwani [/O=THERANOS ORGANIZATION/OU=FIRST ADMINISTRATIVE GROUP/CN=RECIPIENTS/CN=SBALWANI]
Sent:	1/29/2014 8:36:51 PM
To:	Mark Pandori [mpandori@theranos.com]
Subject:	RE: processes around samples and results
	o create a culture of responsibility and ownwership in CLIA and until the PM team is involved baby sitting
-	nd processes, this wont happen. They can help when and where needed and asked by you. But this should be a cision you should make.
Thanks.	
From: Mar	'k Pandori
Sent: Wed	nesday, January 29, 2014 12:34 PM
To: Sunny	Balwani
Subject: R	E: processes around samples and results
I will begin	
Sent from	my Windows Phone
From: Sun	ny Balwani
Sent: 1/29	/2014 12:32 PM
To: Mark F	<u>'andori</u>
Subject: p	rocesses around samples and results
Mark.	
Can you pl	ease review all SOPs and process in light of our discussion from yesterday and this issue with results and 27
hour turn	around time – to see what we can do to create a perfect experience and processes and responsibilities.
I would like	e the product management team 100% out of any CLIA matters asap — except for demos.
Thanks.	

1601 S. California Ave.

Sunny Balwani

Theranos Inc. 650-320-2777

President & COO

Confidential THPFM0004043512

sbalwani@theranos.com

IMPORTANT – This electronic transmission, and any files transmitted with it are confidential and/or legally privileged information. This information is intended solely for the use of the individual or entity to which it is addressed. Any disclosure, retransmission, reproduction, dissemination or other use of the contents of this information by persons or entities other than the intended recipient is strictly prohibited. If you have received this email in error, please contact us immediately and delete all copies. Please note that any views or opinions presented in this email are solely those of the author and do not necessarily represent those of Theranos, Inc. Finally, before opening or using attachments the recipient should check this email and any attachments for the presence of viruses. Theranos, Inc. accepts no liability for any damage caused by any virus transmitted by this email. Our sole responsibility is limited to resupplying any affected attachments.

Confidential THPFM0004043513